Thor Halfdanarson, Professor of Oncology at Mayo Clinic School of Medicine, shared a post on X:
”Is Blinded Independent Central Review (BICR) needed in hematology/oncology trials?
According to this meta-analysis there is a good concordance between investigators and BICR.
Is BICR worth the investment?
Can we use that money better for other trial support?”
Title: Concordance in Assessments Between Investigators and Blinded Independent Central Review (BICR) in Hematology Oncology Clinical Trials: A Meta-Analysis
Authors: Xiaoyu Tang, Yang Dang, Siying Han, Bohan Cui, Yi Kang, Xiaoyu Luo, Hui Zhang
Read the Full Article.
More posts featuring Thor Halfdanarson.